WALTHAM, Mass., June 8 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN - News) today reported results for the fourth quarter and fiscal year ended March 31, 2006. Total revenue for fiscal year 2006 was $12,911,000 compared to total revenue of $9,360,000 for the fiscal year ended March 31, 2005, an increase of $3,551,000. Product revenue for fiscal year 2006 consisting of Protein A and SecreFlo® sales, was $12,529,000 compared to $9,360,000 for fiscal year 2005, an increase of 34%. Gross profit on product revenue for fiscal year 2006 was $8,978,000 (72%) compared to $5,472,000 (58%) for fiscal year 2005. The increase in product revenue was primarily due to higher customer demand. Profit margin was impacted favorably by higher revenue and the decreased royalty owed for SecreFlo®, our secretin product which is marketed to gastroenterologists for diagnosis of pancreatitis and gastrinoma, a rare form of cancer.
